Microbiota, a key player in alcoholic liver disease

Area of Science:

• Gastroenterology
• Hepatology
• Microbiology

Background:

• Alcoholic liver disease (ALD) is a significant global health burden.
• Intestinal microbiota (IM) dysbiosis is increasingly recognized in ALD pathogenesis.
• Gut barrier dysfunction, characterized by reduced tight junction proteins and mucin, precedes liver injury.

Purpose of the Study:

• To explore the role of the intestinal microbiota in the development and progression of alcoholic liver disease.
• To investigate the impact of gut barrier integrity on ALD.
• To evaluate the potential of microbiome-targeted therapies for ALD management.

Main Methods:

• Review of existing literature on the interplay between gut microbiota and liver injury in ALD.
• Analysis of common features of ALD, including gut barrier defects and endotoxemia.
• Examination of bacterial metabolites and their role in ALD pathology.

Main Results:

• Disruption of the gut barrier allows bacterial products (endotoxemia) to enter circulation, contributing to liver damage.
• Bacterial metabolites like short-chain fatty acids, volatile organic compounds, and bile acids are implicated in ALD.
• Interventions altering the gut microbiota, such as probiotics and dietary fiber, show promise in animal models.

Conclusions:

• The intestinal microbiota is a critical factor in ALD.
• Targeting the microbiome with prebiotics, probiotics, or postbiotics offers a potential therapeutic strategy for ALD.
• Further research into the mechanisms underlying host-microbiome interactions in ALD is warranted.